Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$83 Mln
P/E Ratio
--
P/B Ratio
4.71
Industry P/E
--
Debt to Equity
0.01
ROE
-1.38 %
ROCE
-137.61 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
CA$-108.70 Mln
EBITDA
CA$-167.55 Mln
Net Profit
CA$-142.58 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
| -22.34 | -11.24 | -19.18 | -43.84 | -16.70 | -10.69 | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
| 65.29 | -72.43 | -33.45 | -39.30 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 4.26 | 243.69 | 23.37 | 2 | |
| 1.18 | 214.56 | -- | -83.54 | |
| 1.06 | 143.14 | -- | -- | |
| 1.39 | 360.21 | -- | -8.08 |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in... Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 Read more
President, CEO & Director
Mr. David G. Elsley MBA
President, CEO & Director
Mr. David G. Elsley MBA
Headquarters
Oakville, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cardiol Therapeutics Inc Class A (CRDL) stood at $ 32 Mln as on 31-Dec-24
The share price of Cardiol Therapeutics Inc Class A (CRDL) is $0.99 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Cardiol Therapeutics Inc Class A (CRDL) has given a return of -16.7% in the last 3 years.
Cardiol Therapeutics Inc Class A (CRDL) has a market capitalisation of $ 83 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cardiol Therapeutics Inc Class A (CRDL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cardiol Therapeutics Inc Class A (CRDL) and enter the required number of quantities and click on buy to purchase the shares of Cardiol Therapeutics Inc Class A (CRDL).
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
The CEO & director of Mr. David G. Elsley MBA. is Cardiol Therapeutics Inc Class A (CRDL), and CFO & Sr. VP is Mr. David G. Elsley MBA.
There is no promoter pledging in Cardiol Therapeutics Inc Class A (CRDL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
49
|
|
|
45
|
|
|
26
|
|
|
19
|
| Cardiol Therapeutics Inc Class A (CRDL) | Ratios |
|---|---|
|
Return on equity(%)
|
-138.47
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cardiol Therapeutics Inc Class A (CRDL) was $0 Mln.
$0.02
(
